The Impact of COVID-19 Pandemic on Female Sexual Function.

Introduction: The outbreak of the COVID-19 pandemic affected many aspects of life involving sexual functioning. Methods: This prospective, noninterventional, observational research was performed from July 2020 to August 2020, involving a total of 644 patients. Female sexual function index (FSFI) scores of those women were compared in relation to results of our research from April 2020. Questionnaires were collected concerning socio-demographic characteristics of patients as well as the impact of the COVID-19 pandemic on their lives. Results: Every domain significantly decreased in the first month of the lockdown. Before the pandemic, the total FSFI was reported at 30.1 ± 4.4, while in the first month of the pandemic it was at 25.8 ± 9.7 (p < 0.001). The lowest FSFI score was reported by women who lived in average conditions. There was a statistically significant increase in the overall FSFI score in the fifth month of the pandemic (27.5 ± 6.8) when compared to the FSFI score in the first month of the pandemic (25.8 ± 9.7). The scores in arousal, lubrication, orgasm and pain were reported as higher (respectively p < 0.001, p < 0.001, p < 0.001, p < 0.05), while desire was reported lower (p < 0.001). The satisfaction score remained almost the same (p < 0.05). Conclusions: Our study indicates a significant decrease in FSFI scores across all domains. There are still many questions whether the statue from the vaccinated person or convalescents affects the sense of security and, thus, increases sexual satisfaction.

The Impact of COVID-19 on Female Sexual Health.

INTRODUCTION: Coronavirus disease (COVID-19), announced as a pandemic by the World Health Organization, recently has dominated people's lifestyle. The impact of COVID-19 seems to be relevant to the sexual health as well. METHODS: This prospective study was conducted on two occasions involving 764 female patients between March and April 2020-before and during the time of social quarantine. The sexual function was assessed using the Polish version of the Female Sexual Function Index (FSFI). Every patient filled out the survey concerning socio-demographic characteristics as well as the influence of SARS-CoV-2 pandemic on their lives. RESULTS: The overall FSFI score before the pandemic was 30.1 ± 4.4 and changed to 25.8 ± 9.7 during it. Scores of every domain: desire, arousal, lubrication, orgasm, satisfaction and pain decreased as well (p < 0.001). There was statistically significant association between the workplace and the change of FSFI scores before and during COVID-19 pandemic (p < 0.01). We noticed the biggest decrease in FSFI score in the group of women who did not work at all (5.2 ± 9.9). Religion had a statistically important impact on level of anxiety (p < 0.01). CONCLUSION: The main finding of our study was the influence of COVID-19 pandemic on the quality of sexual lifestyle and frequency of intercourse among Polish women.

Anti-androgenic therapy in young patients and its impact on intensity of hirsutism, acne, menstrual pain intensity and sexuality - a preliminary study.

OBJECTIVES: Using anti-androgenic contraception is one of the methods of birth control. It also has a significant, non-contraceptiveimpact on women's body. These drugs can be used in various endocrinological disorders, because of their abilityto reduce the level of male hormones.The aim of our study is to establish a correlation between taking different types of anti-androgenic drugs and intensity ofhirsutism, acne, menstrual pain intensity and sexuality. MATERIAL AND METHODS: 570 women in childbearing age that had been using oral contraception for at least three monthstook part in our research. We examined women and asked them about quality of life, health, direct causes and effects ofthat treatment, intensity of acne and menstrual pain before and after. Our research group has been divided according tothe type of gestagen contained in the contraceptive pill: dienogest, cyproterone, chlormadynone and drospirenone. Additionally,the control group consisted of women taking oral contraceptives without antiandrogenic component. RESULTS: The mean age of the studied group was 23 years ± 3.23. 225 of 570 women complained of hirsutism.The mean score for acne intensity before the use of contraception was 2.7 ± 1.34. The mean score for acne intensity after3 months of using contraception was 1.85 ± 1.02 (p < 0.001). 192 women reported excess hairiness in one or more areabefore treatment. Mean value based on Ferriman-Gallway scale before the treatment was 6.23 ± 6.21 and 5.39 ± 5.6 afterthe treatment (p < 0.001). CONCLUSIONS: All groups of drugs effectively reduced pain and acne severity. Cyproterone and drospirenone turned outas the most effective drugs in treating hirsutism. Surprisingly, according to our research, dienogest does not have anyimpact on body hairiness.